Hims & Hers Health (NYSE: HIMS ) is a telehealth company founded in 2017 on the novel idea of delivering medication for stigmatized conditions without having to talk directly to a doctor. While individuals should not feel embarrassed to see theirHi my name is Alex and I like investing in stocks. I will always be honest and upfront about my position sizing. I like researching stocks and investing. My goal is to provide deep and easy to understand analysis on various businesses. Before investing in stocks I u ...

核心观点 - Hims & Hers Health (HIMS) 股票近期呈现下跌趋势，主要受到宏观趋势和GLP-1相关新闻的影响，但仍被视为值得关注的成长型股票 [1] 股票表现 - Hims & Hers Health (HIMS) 股票价格在2024年12月18日收盘时下跌了7.67% [1] 市场背景 - 股票价格的下跌与宏观趋势和GLP-1相关新闻有关 [1] 投资建议 - 尽管股票充满噪音，但投资者应关注其潜在的成长性 [1]

One of 2024's best stocks is at an intriguing entry pointHims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss drug craze -- is taking a hit after the Food and Drug Administration (FDA) announced Eli Lilly's (LLY) weight-loss drug shortage was resolved. HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth ...

Telehealth — a new frontier in healthcare that seeks to apply the creature comforts of the digital age to medical services is a field that carries much promise. However, most telehealth stocks haven’t exactly been performing well as of late.There’s no big mystery as to why — the COVID-19 pandemic saw a sudden surge in utilization, but as soon as in-person healthcare services resumed, demand dried up significantly. On top of that, this is a field with no shortage of regulatory and legal risks — while the rap ...

Hims & Hers Health, Inc. (HIMS) has emerged as a transformative player in the personalized healthcare market, showcasing robust growth in 2024. Shares of the company have risen 43% in the past month, significantly outperforming the industry’s growth of 5.5%.In the third quarter, the company reported revenues of $401.6 million, reflecting a 77% year-over-year increase. Earnings per share (EPS) of 32 cents met the analyst expectations. The company now boasts over 2 million subscribers, of which more than 50% ...

With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the latest and highest-quality analysis of this type of information.Hims & Hers Health, Inc. (NYSE: HIMS ) is a San Francisco-based $6.7-billion market cap firm that provides a telehealth solution that links people with qualified doctors in the US, the UK, and throughoutHe leads the investing group Beyond the Wall In ...

Hims & Hers Health, Inc. (NYSE: HIMS ) stock is still substantially undervalued even after a massive YTD rally. A 35% discount looks extremely attractive because HIMS is a very promising business that successfully capitalizes on robust secular trendsComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies p ...

The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University in Baltimore, Maryland, and also serves as the chief medical officer at Sesame, an online telehealth platform. As an avid supporter of telemedicine, his appointment as the FDA chief, upon Senate approval, would benefit telehealth companies and their stocks. Here are two telehealth stocks in th ...

公司概述 - Hims & Hers Health, Inc. (NYSE: HIMS) 是一家利用技术平台提供个性化、可及性强的健康和保健服务的公司，引领快速增长的健康和保健市场 [1] - 公司是订阅式医疗保健的先驱，推动了可观的收入和订阅用户增长 [1] 分析师背景 - Yiannis Zourmpanos 是 Yiazou IQ 的创始人，该平台提供 AI 驱动的股票研究报告 [1] - 分析师曾在 Deloitte 和 KPMG 从事外部/内部审计和咨询工作 [1] - 分析师拥有特许公认会计师资格，是 ACCA 全球的资深会员，并拥有英国商学院的学士和硕士学位 [1] 投资风格 - 专注于 GARP/价值股票，即高质量、价格合理的业务，具有强大的护城河和显著的增长潜力 [1] - 优先考虑基本面，寻找交易价格低于内在价值的股票，并确保有明确的边际安全 [1] - 采用长期投资方法（5-7 年），旨在通过复利积累财富，同时强调下行保护，并在市场不确定性期间采取逆向观点 [1]

Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.Shares of Hims & Hers (HIMS 0.61%) jumped as much as 23% in trading on Monday after President Trump announced his new Food and Drug Administration (FDA) chief, who happens to have ties to a business similar to Hims & Hers. In this video, Travis Hoium covers why this is important and why the stock is moving as fast as it is.*Stock prices used were end-of-day prices of Nov. 25, 2024. The vi ...